FDA Says It Is Working On Compounding Policy Despite Inactive Reg List

A top FDA official told state regulators Tuesday (Sept. 26) that FDA is actively working to finalize a number of policy documents meant to regulate the growing compounding outsourcing sector, but multiple related regulations cited by the official are also on the inactive list of FDA’s most recent regulatory agenda. While Anna Abram, deputy commissioner for policy, planning, legislation, and analysis, did not mention that these regs had been shifted to the backburner of the regulatory agenda, another FDA officially...